Evidence map›Paper›PMID 32071842›Full record

ArticleJIMD reports2020

Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients.

Hossein Moravej, Ruqaiah Altassan, Jaak Jaeken, Gregory M Enns, Carolyn Ellaway, Shanti Balasubramaniam, Pascale De Lonlay, David Coman, Saadet Mercimek-Andrews, Peter Witters and 1 more

Open access · goldAbstract read
In one paragraph

Article in JIMD reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Hyperinsulinemic Hypoglycemia Due toPediatric reports · 2022
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Hossein MoravejNeonatal Research Center Shiraz University of Medical Sciences Shiraz Iran.ORCID https://orcid.org/0000-0002-8435-8039
Ruqaiah AltassanMedical Genetic Department McGill University Health Center Montreal Québec Canada.
Jaak JaekenCenter for Metabolic Diseases University Hospital Gasthuisberg Leuven Belgium.
Gregory M EnnsBiochemical Genetics Program Stanford University Stanford California.
Carolyn EllawayGenetic Metabolic Disorders Service Sydney Children's Hospital Network Sydney New South Wales Australia.
Shanti BalasubramaniamWestern Sydney Genetics Program The Children's Hospital at Westmead Sydney New South Wales Australia.
Pascale De LonlayReference Center for Metabolic Diseases Hospital Necker, University Paris V Paris France.
David ComanDepartment of Metabolic Medicine The Lady Cilento Children's Hospital Brisbane Queensland Australia.
Saadet Mercimek-AndrewsDivision of Clinical and Metabolic Genetics, Department of Pediatrics University of Toronto Toronto Ontario Canada.
Peter WittersMetabolic Center University Hospitals Leuven Leuven Belgium.
Eva MoravaDepartment of Clinical Genomics Mayo Clinic Rochester Rochester Minnesota.ORCID https://orcid.org/0000-0001-7441-700X
The University of Sydney · AUGriffith University · AUHôpital Necker-Enfants Malades · FRMayo Clinic · USMcGill University Health Centre · CARega Institute for Medical Research · BEShiraz University of Medical Sciences · IRStanford University · USUniversitair Ziekenhuis Leuven · BEUniversity of Toronto · CA

Funding

Pilot and Feasibility CoreU54NS115198 · NINDS · MAYO CLINIC ROCHESTER · PI LAM, CHRISTINA · 2019 to 2023
$8.2M
NINDS NIH HHS U54 NS115198
6 · The paper itself

Abstract

backgroundPhosphomannomutase 2 deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation (CDG). Hypoglycemia has been reported in various CDG including PMM2-CDG. The frequency and etiology of hypoglycemia in PMM2-CDG are not well studied.

methodsWe conducted a systematic review of the literature on genetically and/or biochemically confirmed PMM2-CDG patients who developed hypoglycemia. Prospective follow-up information on the patients who received diazoxide therapy was collected and evaluated.

resultsA total of 165 peer-reviewed articles reporting on 933 PMM2-CDG patients were assessed. Hypoglycemia was specifically mentioned only in 23 of these patients (2.5%). Hyperinsulinism was identified in 10 patients (43% of all hypoglycemic patients). Among these 10 patients, seven were successfully treated with diazoxide. However, most patients remained on therapy longer than a year to stay free of hypoglycemia.

conclusionHypoglycemia is a rarely reported finding in patients with PMM2-CDG. Diazoxide-responsive hyperinsulinism was found to have a good prognosis on medication in our PMM2-CDG patients with hypoglycemia. No genotype-phenotype correlation was observed with respect to hyperinsulinism. A prospective study should be undertaken to explore the hypothesis that hypoglycemia is underdiagnosed in PMM2-CDG and to evaluate whether hyperinsulinism is always associated with hypoglycemia.

Indexed as

CDGcongenital disorder(s) of glycosylationdiazoxidehyperinsulinismhypoglycemiaphosphomannomutase 2PMM2‐CDG

Identifiers

PMID32071842
PMCPMC7012739
OpenAlexW2990750233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.